menu
    • menu
    [{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Peficitinib Hydrobromide","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Menarini","highestDevelopmentStatusID":"12","companyTruncated":"Astellas Pharma \/ Menarini"}]

    Find Clinical Drug Pipeline Developments & Deals for Peficitinib Hydrobromide

    Menu

    Peficitinib Hydrobromide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Astellas Pharma

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peficitinib Hydrobromide

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Menarini

                            Deal Size : $5.9 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in ...

                            Details : Under the agreement, Menarini will develop, manufacture and commercialise orally administered Janus kinase (JAK) inhibitor Smyraf Tablets (generic name: peficitinib hydrobromide) in Taiwan for the treatment of rheumatoid arthritis.

                            Brand Name : Smyraf

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 12, 2023

                            Lead Product(s) : Peficitinib Hydrobromide

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Menarini

                            Deal Size : $5.9 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth